Follow the Grifols, S.A. share price and the full insider trade history of the company, a publicly traded company based in Spain. Shares are quoted on ES ES, under the oversight of CNMV. Operating in the Health Care sector, Grifols, S.A. has published 9 insider filings. Market capitalisation: €6.1bn. The latest transaction was filed on 3 July 2026 (Other). Among the most active insiders: Victor Grifols Deu. All data is accessible without an account.
9
Insider Decl.
0
Thresholds
€8m
3 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Grifols, S.A. Buy (bullish), based on 12 analysts. Average price target: €14.40.
41Σ signal
Buys €8m· Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 10,281 of 25,936 companies
57.3
score / 100
Value
72
Quality
43
FCF yld10%
Earn yld6.5%
EV/EBITDA9.6x
ROE6.1%
Gross mgn38%
Net mgn5.3%
Debt/EBITDA5.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
100,000 shares@ €8.960.014% mcap100.0% of flowShareXXXXCNMV:2023075288
9 of 9 declarations
About Grifols, S.A.
Grifols, S.A. is a Spanish company specializing in the healthcare and pharmaceutical sector, known for its plasma-derived products. It is listed on the Spanish stock market, XMAD.